Our group recently reported the strong anti-inflammatory effects of
geniposide (Gen), a bioactive
iridoid glucoside derived from gardenia jasminoides, in a mouse
acute lung injury model. Herein, we hypothesized that Gen might also have potential therapeutic benefits in treatment of
asthma, which was tested in a mouse model of
ovalbumin (Ova)-induced allergic airway
inflammation. Ova-sensitized and -challenged BALB/c mice, as compared with control animals, displayed
airway hyperresponsiveness (AHR), bronchoalveolar lavage
eosinophilia, mucus hypersecretion, and increased T help 2 (Th2)-associated
cytokine and
chemokine amounts, as well as serum Ova-specific
immunoglobulin E (
IgE) level. Being compared with the Ova-induced hallmarks of
asthma, intraperitoneal Gen treatment prevented eosinophilic pulmonary infiltration, attenuated the increases in
interleukin (IL)-4,
IL-5, and
IL-13, and reduced eotaxin and
vascular cell adhesion molecule 1 (VCAM-1) expression. Also, Gen significantly ameliorated the Ova-driven
airway hyperresponsiveness, mucus hypersecretion, and
allergen-specific
IgE level, which are the cardinal pathophysiological symptoms in allergic airway diseases. In addition, the efficacy of Gen was comparable to that of
dexamethasone (Dex), a currently available
anti-asthmatic drug. Collectively, our findings reveal that the development of immunoregulatory strategies based on Gen may be considered as an effective adjuvant
therapy for allergic
asthma.